arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Boundless Bio, Inc.

BOLD

$2.90 ▲ +0.05 (+1.75%) at close

13 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Boundless Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $65.0M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -13.2% ↘

FCF / Share $-0.67

Trailing P/E —

Price / Book 0.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

13-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-13.55M

↑ +14.0% —

FCF / Share Free cash flow per share

$-0.67

↓ -2.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗
EPS Growth YoY (%)	15.5% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	9.5% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	16.2% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	9.1% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	94.2% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	93.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	93.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	92.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-23.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	14.0% Fair ↓ Fair Declining Year-over-year change in net income	21.7% Good ↑ Good Improving Year-over-year change in net income	15.9% Good ↑ Good Improving Year-over-year change in net income	7.7% Fair ↑ Fair Improving Year-over-year change in net income	-2.1% Weak ↑ Weak Improving Year-over-year change in net income	-35.4% Weak ↓ Weak Declining Year-over-year change in net income	-25.3% Weak ↑ Weak Improving Year-over-year change in net income	-36.9% Weak Weak Year-over-year change in net income	-31.7% Weak Weak Year-over-year change in net income	—	—	—	—
FCF Growth YoY (%)	-2.2% Weak Weak Year-over-year change in free cash flow	—	—	—	94.8% Excellent Excellent Year-over-year change in free cash flow	—	—	—	-22.5% Weak Weak Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗
FCF / Net Income (x)	1.11x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	1.03x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.04x Fair Fair Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗
Return on Invested Capital (%)	-13.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	9.4% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	8.6% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-10.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-8.9% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-9.0% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-9.5% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-9.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-8.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-10.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-10.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-14.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-10.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—
Return on Common Equity (%) (%)	-15.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-205%)	-13.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-187%)	-12.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-184%)	-12.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-185%)	-11.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-177%)	-10.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-173%)	-10.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-167%)	-9.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-163%)	10.9% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-27%)	9.6% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-36%)	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗
Net Debt (USD)	$-17.48M	$-17.87M	$-14.98M	$-14.70M	$-15.12M	$-26.59M	$-40.21M	$-31.36M	$-25.14M	$-23.71M	$-20.96M	$-41.32M	$-21.06M

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗
Basic EPS, GAAP (USD)	$-0.60	$-0.57	$-0.62	$-0.70	$-0.71	$-0.63	$-0.74	$-0.77	$-12.27	$-9.76	$-10.71	$-10.28	$-9.91
Free Cash Flow per Share (USD)	$-0.67	—	$-0.46	$-0.53	$-0.65	—	—	—	$-12.61	—	$-10.03	$-9.14	$-10.29
Book Value per Share (USD)	$3.86	$4.40	$4.92	$5.48	$6.13	$6.76	$7.42	$8.05	$-111.82	—	—	—	—
Tangible Book Value per Share (USD)	$3.86	$4.40	$4.92	$5.48	$6.13	$6.76	$7.42	$8.05	$-111.82	—	—	—	—
Basic Weighted Avg Shares (shares)	22.41M	—	22.39M	22.36M	22.30M	—	22.25M	22.02M	1.26M	—	1.23M	1.21M	1.18M

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗
Working Capital (USD)	$85.03M	$97.07M	$108.31M	$120.48M	$134.03M	$146.25M	$160.44M	$174.18M	$101.52M	$114.84M	—	—	—
Total Equity (USD)	$86.38M	$98.65M	$110.17M	$122.69M	$136.59M	$150.64M	$165.08M	$179.25M	$-141.18M	$-127.08M	—	—	—

📋 What is driving earnings? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗
Depreciation Expense (USD)	$284.00K	$307.00K	$310.00K	$317.00K	$317.00K	$296.00K	—	$265.00K	$263.00K	$247.00K	—	$238.00K	$237.00K
Net Income, GAAP (USD)	$-13.55M	$-12.88M	$-13.88M	$-15.68M	$-15.76M	$-16.45M	$-16.51M	$-16.98M	$-15.43M	$-12.14M	$-13.17M	$-12.40M	$-11.72M
Operating Cash Flow (USD)	$-14.97M	$-10.11M	$-10.20M	$-11.83M	$-14.53M	$-15.56M	—	—	$-15.78M	$-11.69M	$-12.19M	$-10.89M	$-12.09M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 3 years · 13 quarters

Boundless Bio, Inc.

Analytical Summary

13-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BOLD with peers